This study intends to enroll patients with advanced soft tissue sarcoma, employing immunotherapy combined with eribulin, anlotinib, and radiotherapy as subsequent-line treatment to preliminarily explore its efficacy and safety. QL1706, a dual-targeting agent against PD-1 and CTLA-4, has been approved by the National Medical Products Administration (NMPA) of China for the second-line treatment of cervical cancer.
Signed informed consent form;
Subjects aged 14-75 years;
Patients with histologically or cytologically confirmed advanced soft tissue sarcoma (STS);
Patients with STS who have failed first-line or higher treatment;
History of allergy to QL1706 or any of its components, or contraindication to its treatment;
Prior administration of QL1706 or eribulin;
Specific pathological subtypes, such as Ewing sarcoma, non-poly-morphic rhabdomyosarcoma, or gastrointestinal stromal tumor (GIST);
Resistance or intolerance to anlotinib, eribulin, radiotherapy, or any other contraindications to these treatments;